Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

Key Points

• This resolution expresses the opinion of the House of Representatives that the abortion pill mifepristone is safe and effective. It states that government rules for this medicine should be based on 25 years of medical research and scientific evidence rather than political interference.
• The proposal highlights that medication abortion accounted for 63 percent of all abortions in the United States in 2023. It argues that the FDA should protect the ability for patients to receive this medicine through the mail or after a telehealth appointment with a doctor.
• Supporters say this action is necessary because many states have banned abortion since the Supreme Court overturned Roe v. Wade. They argue that restricting this medicine hurts people in rural areas, those with low incomes, and minority groups who may have trouble traveling to a clinic.
• The resolution points out that while mifepristone has a very strong safety record and is used in over 90 countries, it is still regulated more strictly than 99 percent of other prescription drugs. It calls for these rules to be transparent and fair for all patients.

Impact Analysis

Govbase has not yet run an impact analysis on this legislation.